Reports Search Total = 1027

Parkinson’s Disease Drugs Market – Growth, Trends, and Forecast (2019-2024)

Healthcare Published by: Mordor Intelligence Market: Global
111 pages Published: 23-07-2019
  • Healthcare
  • Mordor Intelligence
  • Global
  • 111 pages
  • Published: 23-07-2019

Market Overview

 

Parkinson’s disease is a chronic disorder that gradually leads to progressive deterioration of motor functions, caused by the loss of dopamine-producing brain cells. Parkinson’s disease drugs market is expected to witness significant growth, owing to the increasing cases of Parkinson’s disease, with the growth in aging population levels. Therefore, it may drastically result in increasing the market size during the forecast period. Pharmaceutical firms are developing new and improved therapies for Parkinson’s disease (PD), and recently, there have been some major product launches in Parkinson disease therapeutics and other assistive therapeutics. For instance, Adamas Pharmaceuticals’ amantadine extended-release capsules / Gocovri launched in Jan 2018, which was the first drug indicated for dyskinesia developed due to long-term use of levodopa. 

 

Furthermore, most of the global firms have a robust drug pipeline for the treatment of Parkinson’s disease, and as per the estimates, the forecast period may witness the launch of a few blockbuster drugs.

 

Scope of the Report

 

Parkinson’s disease drugs market has been segmented by the mechanism of action and geography. BY mechanism of action, the market studied is segmented into dopamine agonists, anticholinergic, MAO-B inhibitors, amantadine, carbidopa-levodopa, COMT inhibitors, and other mechanisms of action. By geography, the market is segmented into North America, Europe, Asia-Pacific, South America, and Middle East & Africa.

 

Key Market Trends

 

COMT (Catechol-O-Methyltransferase) Inhibitors are expected to Register Robust growth

 

Carbidopa-levodopa Therapy is the most effective medication for alleviating the motor symptoms of PD. However, it has been observed that this medication is not as effective as intended. Therefore, it is imperative that co-therapeutic agents, such as COMT (catechol-O-methyltransferase) inhibitors, are used along with carbidopa-levodopa therapy. The two most common COMT inhibitors, used in the treatment of Parkinson’s disease, are Comtan (entacapone) and Tasmar (tolcapone). Both these medications are available in the form of tablets. In addition, these medications are routinely prescribed in conjunction with carbidopa-levodopa therapy.

 

The United States Represents the Largest Market for Parkinson’s Disease Therapeutics

 

According to the National Institute of Health, approximately 1.2 million people in the United States are predicted to have Parkinson’s disease by 2030. It is the second-most common neurodegenerative disorder in the United States. In addition, there are thousands of patients who go undetected. As the aging population levels continue to grow, the number of people suffering from Parkinson’s disease (PD) will continue to grow, and this is expected to double by 2040. The sheer number of Parkinson’s disease patients, combined with the availability of reimbursements and high awareness, is boosting the growth of the market. Furthermore, the high cost of Parkinson’s disease therapeutics in the United States also leads to significant market size in terms of revenue. The average cost of Parkinson’s medication is approximately USD 2,500 per year and Parkinson’s-related surgery can cost up to USD 100,000 per patient.

 

Competitive Landscape

 

Parkinson’s disease drugs market is becoming highly competitive. The recent product launches and the high number of therapeutics in product pipelines of global pharmaceutical firms are contributing to the dynamic nature of the market. Several new product launches are expected during the forecast period, which may lead to significant changes in market shares of pharmaceutical firms currently active in the market.

 

Reasons to Purchase this report:

– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Geriatric Population
4.2.2 Recent Drug Approvals
4.2.3 Growing Awareness
4.3 Market Restraints
4.3.1 Generic Competition to Key Therapies
4.3.2 High Cost of Treatment
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Mechanism of Action
5.1.1 Dopamine Agonists
5.1.2 Anticholinergic
5.1.3 MAO-B inhibitors
5.1.4 Amantadine
5.1.5 Carbidopa-levodopa
5.1.6 COMT Inhibitors
5.1.7 Other Mechanisms of Action
5.2 Geography
5.2.1 North America
5.2.1.1 US
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 UK
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East & Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East & Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Merck & Co. Inc.
6.1.2 Impax Laboratories Inc.
6.1.3 AbbVie Inc.
6.1.4 Mylan NV
6.1.5 Boehringer Ingelheim
6.1.6 GlaxoSmithKline plc
6.1.7 M Somerset Pharmaceuticals Inc.
6.1.8 Teva Pharmaceuticals Industries Ltd
6.1.9 Pfizer Inc.
6.1.10 Novartis AG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

MARKET SEGMENTATION

 

By Mechanism of Action
Dopamine Agonists
Anticholinergic
MAO-B inhibitors
Amantadine
Carbidopa-levodopa
COMT Inhibitors
Other Mechanisms of Action

Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America

 

We value your investment and offer free customization with every report to fulfil your exact research needs.

Share This Post:

Choose License Type

Pakistan Crop Protection Chemicals Market – Growth, Trends, and Forecast (2019 – 2024)

Agriculture Published by: Mordor Intelligence Market: Pakistan
85 pages Published: 23-07-2019
  • Agriculture
  • Mordor Intelligence
  • Pakistan
  • 85 pages
  • Published: 23-07-2019

Market Overview

 

The Pakistan crop protection chemicals market is estimated to witness a CAGR of 8.04% over the period, 2019-2024. The market was valued at USD 220.0 million in 2018 and is forecasted to reach a value of USD 349.5 million by 2024.

 

Some important crops in Pakistan include wheat, cotton, paddy, sugarcane, and vegetables, and the area under them is increasing rapidly. Wheat is the core crop in the country and contributes about 37% of the total food energy intake in Pakistan. This large acreage under high pesticide consuming crops acts as a driver for the crop protection market.

 

Scope of the Report

 

Crop protection chemicals constitute a class of agrochemicals used for preventing the destruction of crops by pests, diseases, and weeds. Pesticides form the largest category within the market for crop protection chemicals, with biopesticides comparatively accounting for a minute share.

 

The report contains a detailed analysis of various parameters of the Pakistan crop protection chemicals market (hereafter, referred to as the market studied). The market studied has been segmented, based on chemical type, application, and distribution channel.

 

Key Market Trends

 

The Insecticides Segment is Leading the Crop Protection Market

 

At 58%, the insecticides segment led the crop protection chemicals market in Pakistan in 2018. Synthetic insecticides capture 98% of the insecticides market, while bio insecticides cover the rest. One of the widely used insecticides against whitefly, which is a common cotton pest in Pakistan, is Movento, developed by Bayer CropScience. This insecticide is popular worldwide, as well as in Pakistan, due to its two-way systemic movement making it ideal for many farmers in Pakistan.

 

Large Acreage Under High Pesticide Consuming Crops is Driving the Market

 

Overcoming the yield gaps, pesticide usage is one of the most important components in the crop production system. Insecticides and herbicides are considered to be important inputs to overcome the yield gap. Some important crops in Pakistan include wheat, cotton, paddy, sugarcane, and vegetables, and the area under them is increasing rapidly. Wheat is the core crop in the country and contributes about 37% of the total food energy intake in Pakistan. 

 

Competitive Landscape

 

The Pakistan crop protection chemicals market is consolidated, with many big players occupying a major portion of the market, having a diverse and increasing product portfolio. In terms of market share dominance, Syngenta Pakistan with 21% share is followed by Ali Akbar Group and Arysta LifeSciences Corp., which have a market share of around 19% and 11%, respectively. The higher market share of these players can be attributed to their highly diversified product portfolio.

 

Reasons to Purchase this report:

– The market estimate (ME) sheet in Excel format

– Report customization as per the client’s requirements

– 3 months of analyst support

1 INTRODUCTION

1.1 Market Definition

2 RESEARCH SCOPE AND METHODOLOGY

2.1 Study Deliverables

2.2 Study Assumptions

2.3 Research Methodology

2.4 Research Phases

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Drivers

4.2 Market Restraints

4.3 Porter’s Five Forces Analysis

4.3.1 Bargaining Power of Suppliers

4.3.2 Bargaining Power of Buyers

4.3.3 Threat of New Entrants

4.3.4 Threat of Substitute Products and Services

4.3.5 Competitive Rivalry

5 MARKET SEGMENTATION

5.1 Origin

5.1.1 Synthetic Crop Protection Chemicals

5.1.2 Bio-Based Crop Protection Chemicals

5.2 Chemical Type

5.2.1 Herbicides

5.2.2 Insecticides

5.2.3 Fungicides

5.2.4 Other Chemical Types

5.3 Application

5.3.1 Grains and Cereals

5.3.2 Oilseeds

5.3.3 Commercial Crops

5.3.4 Fruits and Vegetables

5.3.5 Turf and Ornamentals

5.4 Distribution Channel

5.4.1 Private Traders

5.4.2 Government Channel

5.4.3 Direct Channel

5.4.4 Other Distribution Channels

6 COMPETITIVE LANDSCAPE

6.1 Most Adopted Strategies

6.2 Market Share Analysis

6.3 Company Profiles

6.3.1 Bayer CropScience

6.3.2 Syngenta Pakistan

6.3.3 Arysta Lifescience

6.3.4 FMC Corporation

6.3.5 National Insecticide Company Private Limited

6.3.6 Evyol Group

6.3.7 Welcon Chemicals Corporation

6.3.8 ICI Pakistan Private Limited

6.3.9 Ali Akbar Group

6.3.10 Sayban International

6.3.11 Pakistan Agro Chemicals Private Limited

6.3.12 Four Brothers

6.3.13 BASF SE

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

MARKET SEGMENTATION

 

Origin

Synthetic Crop Protection Chemicals

Bio-Based Crop Protection Chemicals

 

Chemical Type

Herbicides

Insecticides

Fungicides

Other Chemical Types

 

Application

Grains and Cereals

Oilseeds

Commercial Crops

Fruits and Vegetables

Turf and Ornamentals

 

Distribution Channel

Private Traders

Government Channel

Direct Channel

Other Distribution Channels

We value your investment and offer free customization with every report to fulfil your exact research needs.

Share This Post:

Choose License Type

Patient Monitoring Market – Growth, Trends, and Forecast (2019 – 2024)

Healthcare Published by: Mordor Intelligence Market: Global
115 pages Published: 23-07-2019
  • Healthcare
  • Mordor Intelligence
  • Global
  • 115 pages
  • Published: 23-07-2019

Market Overview

 

The growth of the patient monitoring (PM) market is attributed to the rising incidences of chronic diseases due to lifestyle changes, growth in geriatric population, growing preference for home and remote monitoring, and ease of use and portability devices to promote the growth.

 

The World Health Organization (WHO) defines chronic disease management as the “ongoing management of conditions over a period of years or decades”. Chronic diseases are the leading cause of mortality and morbidity, representing 77% of all casualties in Europe, and research suggests that complex conditions, such as diabetes and depression are likely to impose a larger burden in the future. Over one-third of the European population above the age of 15 has a chronic disease. Two out of three people reaching retirement age are expected to have at least two chronic conditions, according to the World Health Organization (WHO). Many chronic diseases and conditions are linked to an aging society and lifestyle choices, such as smoking, sexual behavior, diet, and exercise, as well as to genetic predispositions. WHO research shows that the total burden is expected to be even higher in the future if nothing is done about the growth of chronic disease cases now. According to the European Commission, 70% to 80% of healthcare budgets, or an estimated EUR 700 billion per year, is currently spent on chronic diseases in the European Union. Here, PM technologies come into play and identify small changes in the patient’s physiological data, hence promoting self-monitoring. Thus, it reduces readmissions and prevents avoidable hospitalizations. Moreover, these technologies decrease the number of unnecessary trips to the doctor’s office and reduce travel-related expenses. On the short- and long-term basis, by the proper implementation, PM technologies can expand access to quality healthcare and save time and money.

 

Scope of the Report

 

As per the scope of this report, patient monitoring devices are monitoring devices that continuously monitor the patient’s vital parameters, like blood pressure and heart rates, by using a medical monitor and collecting medical (and other) data from individuals.

 

Key Market Trends

 

Home Healthcare is the Segment Under End User that is Expected to Grow Fastest During the Forecast Period

 

The hospitals segment held the maximum share in 2018, owing to high patient turnaround and large volumes of procedures. 

 

The home healthcare segment is anticipated to exhibit a robust growth rate over the forecast period. Cost efficiency of these alternate sites, along with availability qualified resources, is expected to support the growth.

 

North America Region Holds the Largest Market Share of the Patient Monitoring Market Market Currently and is Believed to Follow the Same Trend over the Forecast Period

 

The North American patient monitoring market dominated the global market and is estimated to show a similar trend during the forecast period. The increasing geriatric population, rising incidences of chronic diseases, growing demand for wireless and portable systems, coupled with the presence of sophisticated reimbursement structure aiming toward cutting out of pocket expenditure levels, are the major factors attributing to its large market share.

 

The Asia-Pacific market is expected to grow at the fastest rate over the forecast period, owing to the large presence of untapped opportunities in the emerging markets of India and China, rising medical tourism, and constantly improving healthcare infrastructure in these markets.

 

Competitive Landscape

 

The patient monitoring market consists of several major players. The companies are implementing certain strategic initiatives, such as mergers, new product launch, acquisitions, and partnerships that help them in strengthening their market position. For instance, Roche and Qualcomm entered into strategic collaboration in order to enhance remote monitoring and chronic disease management.

 

Reasons to Purchase this report:

– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incidences of Chronic Diseases due to Lifestyle Changes
4.2.2 Growth in Geriatric Population
4.2.3 Growing Preference for Home and Remote Monitoring
4.2.4 Ease of Use and Portability Devices to Promote the Growth
4.3 Market Restraints
4.3.1 Resistance from Healthcare Industry Professionals Toward the Adoption of Patient Monitoring Systems
4.3.2 Stringent Regulatory Framework
4.3.3 High Cost of Technology
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Type of Device
5.1.1 Hemodynamic Monitoring Devices
5.1.2 Neuromonitoring Devices
5.1.3 Cardiac Monitoring Devices
5.1.4 Multi-parameter Monitors
5.1.5 Respiratory Monitoring Devices
5.1.6 Remote Patient Monitoring Devices
5.1.7 Other Types of Devices
5.2 By Application
5.2.1 Cardiology
5.2.2 Neurology
5.2.3 Respiratory
5.2.4 Fetal and Neonatal
5.2.5 Weight Management and Fitness Monitoring
5.2.6 Other Applications
5.3 By End Users
5.3.1 Home Healthcare
5.3.2 Ambulatory Care Centers
5.3.3 Hospitals
5.3.4 Other End Users
5.4 Geography
5.4.1 North America
5.4.1.1 US
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 UK
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Baxter International Inc.
6.1.3 Boston Scientific Corporation
6.1.4 Becton, Dickinson and Company
6.1.5 GE Healthcare
6.1.6 Honeywell Life Care Solutions
6.1.7 Johnson & Johnson
6.1.8 Masimo Corporation
6.1.9 Medtronic Care Management Services LLC
6.1.10 Omron Corporation
6.1.11 Koninklijke Philips NV
6.1.12 Siemens Healthcare GmbH

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

MARKET SEGMENTATION

 

By Type of Device
Hemodynamic Monitoring Devices
Neuromonitoring Devices
Cardiac Monitoring Devices
Multi-parameter Monitors
Respiratory Monitoring Devices
Remote Patient Monitoring Devices
Other Types of Devices

By Application
Cardiology
Neurology
Respiratory
Fetal and Neonatal
Weight Management and Fitness Monitoring
Other Applications

By End Users
Home Healthcare
Ambulatory Care Centers
Hospitals
Other End Users

Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America

 

We value your investment and offer free customization with every report to fulfil your exact research needs.

Share This Post:

Choose License Type

Pain Management Market – Growth, Trends, and Forecast (2019 – 2024)

Healthcare Published by: Mordor Intelligence Market: Global
111 pages Published: 23-07-2019
  • Healthcare
  • Mordor Intelligence
  • Global
  • 111 pages
  • Published: 23-07-2019

Market Overview

 

The growth of the global pain management drugs and devices market is majorly due to the well-established business of painkiller medications as the first line of treatment. In recent years, the increasing reliance on their prolonged use and a greater understanding of their side-effects have led to the growing use of device-based pain management therapies. Presently, at the country level, economic factors play a significant role in the management of financial implications for hospitals. Postsurgical pain is one of the primary focuses of hospitals, where the cost of monitoring and the treatment of adverse effects creates the major demand for pain management drugs and devices. 

 

The current market is gradually adopting more non-opioid medications to suppress the addiction toward opioids and certain well-established painkillers in the market. There are several non-opioid drugs with mechanisms of action that are currently in early and late-stage development. The federal authorities in multiple countries are shifting to alternative approaches, and thus, fast-tracking those drugs to market approval. The shift is expected to be gradual, and thus pain management has very attractive growth prospects between 2019 and 2024.

 

Scope of the Report

 

This report includes an in-depth study of the global pain management market (henceforth, referred to as the ‘market studied’). Pain is defined as an unpleasant sensation in the body, owing to ongoing or impending tissue damage. Pain management is one of the most frequently dealt-with issues by clinicians for any disease. Pharmacological therapy is the first line of therapy, followed by treatment via devices in severe pain management cases. 

 

Key Market Trends

 

Cancer Pain Segment is Expected to Exhibit the Fastest Growth Rate over the Forecast Period

 

Pain during cancer occurs the most when a tumor presses on to the bones, nerves, or organs. The pain may vary according to the affected location. Chemotherapy, radiotherapy, and surgery can also cause pain. Certain painful conditions are likely to occur more in patients with a suppressed immune system, which is often a result of these therapies.

 

Pain caused by cancer can be treated. About nine out of ten cancer patients suffering from pain find relief by using a combination of medications. Many medicines are used for pain management in cancer patients. Some drugs are general pain relievers, while other target specific types of pain may require a prescription. The increasing incidences of various forms of cancer are likely to directly lead to an increase in cancer pain cases, the treatment of which, both through drugs and devices, is expected to contribute to the market growth.

 

North America Captured the Largest Market Share and is Expected to Retain its Dominance

 

North America holds the largest share in the global pain management market, with the United States being the largest contributor to its revenue. According to the data published by the Centers for Disease Control and Prevention (CDC), in 2016, approximately 20.4% of adults in the United States (which is about 50.0 million) were suffering from chronic pain and 8.0% of adults in the country (which is about 19.6 million) were suffering from high-impact chronic pain, with higher prevalence associated with advancing age. Overall, pain management in the United States is considered to be the most developed in the world, primarily due to the large presence of pain specialist physicians, increasing number of approvals from FDA, and the robust infrastructure for providing pain management services to patients.

 

Competitive Landscape

 

The global pain management market is highly competitive and consists of several major players. The existing major players in the pain management market employ strong competitive strategies, leading to high rivalry among them. Some of the key players in the market are Abbott Laboratories, Astra Zeneca, Baxter International Inc., Becton Dickinson & Company, and Boston Scientific Company, among others. Product advancements and improvement in durable medical equipment by the major players are stiffening the competitive rivalry in the market. 

 

Reasons to Purchase this report:

– The market estimate (ME) sheet in Excel format

– Report customization as per the client’s requirements

– 3 months of analyst support

1 INTRODUCTION

1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Increasing Demand for Long-term Pain Management from the Geriatric Population

4.2.2 High Proven Efficacy of Pain Management Devices for the Treatment of Chronic Pain

4.2.3 Rise in Acute and Chronic Pain as a Result of Chronic Health Conditions

4.2.4 Development of Novel Pain Management Devices

4.3 Market Restraints

4.3.1 Lack of Awareness about the Availability and Use of Pain Management Devices

4.3.2 Shortage of Pain Specialists and the Low Number of Pain Clinics in Several Countries

4.3.3 High Procedural and Purchase Cost of Pain Management Devices

4.4 Porter’s Five Forces Analysis

4.4.1 Threat of New Entrants

4.4.2 Bargaining Power of Buyers/Consumers

4.4.3 Bargaining Power of Suppliers

4.4.4 Threat of Substitute Products

4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

5.1 By Mode of Pain Management

5.1.1 Drugs

5.1.1.1 Opioids

5.1.1.2 Non-narcotic Analgesics

5.1.1.2.1 NSAIDS

5.1.1.2.2 Anesthetics

5.1.1.2.3 Anticonvulsants

5.1.1.2.4 Anti-depressants

5.1.1.2.5 Other Non-narcotic Analgesics

5.1.2 Devices

5.1.2.1 Neurostimulation Devices

5.1.2.1.1 Transcutaneous Electrical Nerve Stimulation (TENS) Devices

5.1.2.1.2 Brain and Spinal Cord Stimulation (SCS) Devices

5.1.2.2 Analgesic Infusion Pumps

5.1.2.2.1 Intrathecal Infusion Pumps

5.1.2.2.2 External Infusion Pumps

5.2 By Application

5.2.1 Neuropathic Pain

5.2.2 Cancer Pain

5.2.3 Facial Pain and Migraine

5.2.4 Musculoskeletal Pain

5.2.5 Other Applications

5.3 Geography

5.3.1 North America

5.3.1.1 United States

5.3.1.2 Canada

5.3.1.3 Mexico

5.3.2 Europe

5.3.2.1 Germany

5.3.2.2 United Kingdom

5.3.2.3 France

5.3.2.4 Italy

5.3.2.5 Spain

5.3.2.6 Rest of Europe

5.3.3 Asia-Pacific

5.3.3.1 China

5.3.3.2 Japan

5.3.3.3 India

5.3.3.4 Australia

5.3.3.5 South Korea

5.3.3.6 Rest of Asia-Pacific

5.3.4 Middle East & Africa

5.3.4.1 GCC

5.3.4.2 South Africa

5.3.4.3 Rest of Middle East & Africa

5.3.5 South America

5.3.5.1 Brazil

5.3.5.2 Argentina

5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.1.1 Abbott Laboratories

6.1.2 AstraZeneca

6.1.3 Baxter International Inc.

6.1.4 Becton Dickinson & Company

6.1.5 Boston Scientific Corporation

6.1.6 Fresenius SE & Co. KGaA

6.1.7 GlaxoSmithKline PLC

6.1.8 Johnson & Johnson

6.1.9 Medtronic PLC

6.1.10 Novartis AG

6.1.11 Pfizer

6.1.12 Teva Pharmaceutical Industries Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

MARKET SEGMENTATION

 

By Mode of Pain Management

Drugs

Opioids

Non-narcotic Analgesics

NSAIDS

Anesthetics

Anticonvulsants

Anti-depressants

Other Non-narcotic Analgesics

Devices

Neurostimulation Devices

Transcutaneous Electrical Nerve Stimulation (TENS) Devices

Brain and Spinal Cord Stimulation (SCS) Devices

Analgesic Infusion Pumps

Intrathecal Infusion Pumps

External Infusion Pumps

 

By Application

Neuropathic Pain

Cancer Pain

Facial Pain and Migraine

Musculoskeletal Pain

Other Applications

 

Geography

North America

United States

Canada

Mexico

Europe

Germany

United Kingdom

France

Italy

Spain

Rest of Europe

Asia-Pacific

China

Japan

India

Australia

South Korea

Rest of Asia-Pacific

Middle East & Africa

GCC

South Africa

Rest of Middle East & Africa

South America

Brazil

Argentina

Rest of South America

We value your investment and offer free customization with every report to fulfil your exact research needs.

Share This Post:

Choose License Type

Overactive Bladder Treatment Market – Growth, Trends, and Forecast (2019 – 2024)

Healthcare Published by: Mordor Intelligence Market: Global
111 pages Published: 23-07-2019
  • Healthcare
  • Mordor Intelligence
  • Global
  • 111 pages
  • Published: 23-07-2019

Market Overview

 

– The overactive bladder (OAB) treatment market is expected to register a CAGR of 2.9% during the forecast period. The increasing incidence of diseases, such as Parkinson’s disease, which lead to the overactive bladder disorder and rising geriatric population are primary drivers of the global market.

– In 2017, there were approximately 950 million people who were 60 years old or above, comprising 13% of the global population, and is growing by about 3% every year. Urinary incontinence generally increases with aging. OAB has a major negative impact on quality of life and health of the aged population.

–  With the increasing burden of OAB, along with other urinary diseases, the growth of the overactive bladder treatment market is likely to be high. Other factors, such as the development of innovative intravesical therapies and aggressive marketing by pharmaceuticals companies, are also expected to expand the market.

 

Scope of the Report

 

The overactive bladder treatments include various therapies, like, anticholinergics, mirabegron, etc., that are used to treat the sudden involuntary contraction of the muscle in the urinary bladder wall, leading to urinary urgency, frequency, nocturia, and urge incontinence.

 

Key Market Trends

 

Idiopathic Overactive Bladder Treatment is Expected to Have the Largest Share

 

Segmented by disease type, the idiopathic overactive bladder treatment accounted for a major share of the market, in 2017, which can be attributed to its high prevalence. Due to the bladder muscle weakness post pregnancy and menopause, women are more vulnerable to the condition. This is expected to encourage key companies to invest in this segment. Increasing competition among the market players may lead to a decrease in the overall cost of treatment, during the forecast period.

 

North America is Expected to Dominate the Overactive Bladder Treatment Market

 

North America is expected to lead the overactive bladder treatment market. This can be credited to its well-established healthcare industry. With reimbursement of overactive bladder treatment, the growing prevalence of the disease with rising age, and the presence of major players, the market is expected to grow during the forecast period. Due to the increasing prevalence of bladder over-activity, geriatric population, healthcare expenditure, and awareness about overactive bladder treatments, the Asia-Pacific region is expected to register the highest CAGR during the forecast period.

 

Competitive Landscape

 

The overactive bladder treatment market is moderately fragmented with global pharmaceutical companies controlling significant market share, moreover, the generic space of the market is observing a trend of consolidation and high competition. Major market players include Allergan PLC, Astellas Pharma Inc., Cogentix Medical Inc., Endo International PLC, Hisamitsu Pharmaceutical Co. Inc., Johnson & Johnson, Medtronic PLC, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Limited, and Macleods Pharmaceuticals Ltd, among others.

 

Reasons to Purchase this report:

– The market estimate (ME) sheet in Excel format

– Report customization as per the client’s requirements

– 3 months of analyst support

1 INTRODUCTION

1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Aging Population and Increasing Prevalence of Diseases Causing Overactive Bladder

4.2.2 Increasing Trend of Drug Development for Overactive Bladder Treatment

4.3 Market Restraints

4.3.1 Side Effects of Current Treatments

4.4 Porter’s Five Forces Analysis

4.4.1 Threat of New Entrants

4.4.2 Bargaining Power of Buyers/Consumers

4.4.3 Bargaining Power of Suppliers

4.4.4 Threat of Substitute Products

4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

5.1 By Therapy

5.1.1 Anticholinergics

5.1.2 Mirabegron

5.1.3 Neurostimulation

5.1.4 Intravesical Instillation

5.1.5 Other Therapies

5.2 By Disease Type

5.2.1 Idiopathic Overactive Bladder

5.2.2 Neurogenic Overactive Bladder

5.3 Geography

5.3.1 North America

5.3.1.1 US

5.3.1.2 Canada

5.3.1.3 Mexico

5.3.2 Europe

5.3.2.1 Germany

5.3.2.2 UK

5.3.2.3 France

5.3.2.4 Italy

5.3.2.5 Spain

5.3.2.6 Rest of Europe

5.3.3 Asia-Pacific

5.3.3.1 China

5.3.3.2 Japan

5.3.3.3 India

5.3.3.4 Australia

5.3.3.5 South Korea

5.3.3.6 Rest of Asia-Pacific

5.3.4 Middle East & Africa

5.3.4.1 GCC

5.3.4.2 South Africa

5.3.4.3 Rest of Middle East & Africa

5.3.5 South America

5.3.5.1 Brazil

5.3.5.2 Argentina

5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.1.1 Allergan PLC

6.1.2 Astellas Pharma Inc.

6.1.3 Cogentix Medical Inc.

6.1.4 Endo International PLC

6.1.5 Hisamitsu Pharmaceutical Co. Inc.

6.1.6 Johnson & Johnson

6.1.7 Medtronic PLC

6.1.8 Pfizer Inc.

6.1.9 Sanofi

6.1.10 Teva Pharmaceutical Industries Limited

6.1.11 Macleods Pharmaceuticals Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

MARKET SEGMENTATION

 

By Therapy

Anticholinergics

Mirabegron

Neurostimulation

Intravesical Instillation

Other Therapies

 

By Disease Type

Idiopathic Overactive Bladder

Neurogenic Overactive Bladder

 

Geography

North America

US

Canada

Mexico

Europe

Germany

UK

France

Italy

Spain

Rest of Europe

Asia-Pacific

China

Japan

India

Australia

South Korea

Rest of Asia-Pacific

Middle East & Africa

GCC

South Africa

Rest of Middle East & Africa

South America

Brazil

Argentina

Rest of South America

We value your investment and offer free customization with every report to fulfil your exact research needs.

Share This Post:

Choose License Type

Pediatric Clinical Trials Market – Growth, Trends, and Forecast (2019 – 2024)

Healthcare Published by: Mordor Intelligence Market: Global
111 pages Published: 23-07-2019
  • Healthcare
  • Mordor Intelligence
  • Global
  • 111 pages
  • Published: 23-07-2019

Market Overview

 

The major factors for the growth of the pediatric clinical trials market include the rising awareness about pediatric medicine, shifting in-house clinical trials to CROs, and increasing burden of pediatric diseases, such as diabetes.

 

Over the last decade, the pharmaceutical industry has been gradually shifting from in-house clinical research to contract research organization (CRO). Until the end of the 20th century, the majority of pharmaceutical companies structured out and executed clinical trials on their own, in their premises. Only small companies with fewer resources (in terms of money, manpower, and minutes) outsourced their clinical research work to CROs. As time progressed, even big companies began outsourcing their work. Thus, the competitive landscape in the field of CROs has increased rapidly. An increasing number of CROs were added to the list, globally, providing reliable and effective offerings to companies. Due to the increase in the number of CROs, pharmaceutical companies started increasing their research practices. In the past few years, organizations, such as IQVIA, PAREXEL, PPD, and others, have gained the confidence of big pharmaceutical companies and are performing well. Pediatric clinical trials have also gained importance as a result of this shift, as companies can now conduct more clinical trials (including pediatrics that was left out before, owing to uncertain returns and lack of resources). 

 

The ease of outsourcing clinical trials is boosting the practice of pediatric clinical trials, and thereby, the market for the same. In the coming years, with the increasing importance of pediatric medicine, the market for pediatric clinical trials is expected to record steady growth.

 

Scope of the Report

 

As per the scope of the report, clinical trials conducted on children, for the R&D of new drugs, are called pediatric clinical trials. Due to the increasing awareness about pediatric medicine, the need to effectively tackle diseases in children, FDA supporting pediatric clinical trial research, and others, the global pediatric clinical trials market is growing. There are various factors that are restraining the market, which include the lack of infrastructure for pediatric clinical trials and ethical issues.

 

Key Market Trends

 

Phase ll Segment under Phase-wise Segmentation is expected to hold the Largest Market Share during the Forecast Period

 

Phase II is the step after Phase l for any biopharmaceutical company to proceed where clinical efficacy or biological activity (‘proof of concept’ studies) and optimum dose to show biological activity with minimal side-effects (‘definite dose-finding’ studies) are performed in 100-300 patients with the specific disease. The time period is several months to two years in most scenarios. The success rate in this phase drops down sharply, and as per the US FDA, the successful trials moving forward are around 33%. As per the clinicaltrials.gov, nearly 5,849 studies are currently in process 2019 with active study undergoing

.

 Owing to high uncertainty and the complex procedure of data collection, analysis, and representation as per government protocols, the pharmaceutical companies generally outsource the clinical trials to the clinical research organizations (CROs) with expertise in various protocols/guidelines laid down by governments across the globe. The rising number of collaborations of companies with hospital chains and CROs with a focus on niche therapeutic segments act as the major driving factors for the success and approval of candidates in this phase. The emerging markets are a rising source of CROs and diversified patient pool for the growth of success rate in phase II. Thus, owing to all the above-mentioned factors, the market is expected to witness high growth over the forecast period.

 

North America is expected to account for the Largest Market Share in the Global Market

 

North America is found to hold a significant share for the pediatric clinical trials market and is expected to show a similar trend over the forecast period. The pediatric clinical trials scenario in the United States has been fluctuating since 2005. The number of clinical trials conducted on the pediatric population in the United States has been increasing since 2005-2009. 

 

However, from 2009-2011, almost an equal number of pediatric clinical trials were performed in the United States. According to the ClinicalTrials.gov, in 2019, more than 3,363 pediatric research procedures were conducted in the United States, which represented a large proportion of the overall global count of pediatric research procedures. The high number of trials and high cost per procedure and patient have largely contributed to the market in the United States. This has made the US pediatric clinical trials market the largest in the world. The population of children in the United States is more than a quarter of the total population, but the pediatric clinical trials performed are ten times lesser than the non-pediatric ones. This is mainly because of ethical issues related to pediatric research and the complexity involved. Another major factor restraining the market is the relatively small target population for the end product.

 

Competitive Landscape

 

The market studied is consolidated, owing to the presence of a few key players in the market. Some of the market players are Bristol – Myers Squibb, Charles River Laboratories International Inc., Covance Inc., ICON plc, IQVIA, Novartis AG, Pfizer, Inc., Pharmaceutical Product Development, LLC, and Syneos Health Inc.

 

Reasons to Purchase this report:

– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Awareness about Pediatric Medicine
4.2.2 Shifting In-house Clinical Trials to CROs
4.2.3 Increasing Burden of Pediatric Diseases, such as Diabetes
4.3 Market Restraints
4.3.1 Ethical Issues in Pediatric Research
4.3.2 Small Size of Study Population
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Phase
5.1.1 Phase I
5.1.2 Phase II
5.1.3 Phase III
5.1.4 Phase IV
5.2 By Study Design
5.2.1 Treatment Studies
5.2.1.1 Randomized Control Trial
5.2.1.2 Adaptive Clinical Trial
5.2.1.3 Non-randomized Control Trial
5.2.2 Observational Studies
5.2.2.1 Cohort Study
5.2.2.2 Case-Control Study
5.2.2.3 Cross-Sectional Study
5.2.2.4 Ecological Study
5.3 Geography
5.3.1 North America
5.3.1.1 US
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 UK
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bristol-Myers Squibb Company
6.1.2 Charles River Laboratories International Inc.
6.1.3 Covance Inc.
6.1.4 GlaxoSmithKline plc
6.1.5 ICON plc
6.1.6 IQVIA
6.1.7 Novartis AG
6.1.8 Pfizer, Inc.
6.1.9 Pharmaceutical Product Development, LLC
6.1.10 Syneos Health Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

 

MARKET SEGMENTATION

By Phase
Phase I
Phase II
Phase III
Phase IV

By Study Design
Treatment Studies
Randomized Control Trial
Adaptive Clinical Trial
Non-randomized Control Trial
Observational Studies
Cohort Study
Case-Control Study
Cross-Sectional Study
Ecological Study

Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina

Rest of South America

 

We value your investment and offer free customization with every report to fulfil your exact research needs.

Share This Post:

Choose License Type